OPTINOSE INC. - COMMO

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights

12 نوفمبر 2024 06:00:12 بحسب Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Third Quarter 2024 Financial Results

05 نوفمبر 2024 15:30:00 بحسب Nasdaq GlobeNewswire

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 أكتوبر 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Optinose Appoints Terry Kohler as Chief Financial Officer

07 أكتوبر 2024 15:59:53 بحسب Nasdaq GlobeNewswire

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery

05 سبتمبر 2024 08:00:50 بحسب Nasdaq GlobeNewswire

Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference

26 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights

08 أغسطس 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Second Quarter 2024 Financial Results

02 أغسطس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Expanded Access to XHANCE with Addition to National Commercial Formularies

27 يونيو 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

17 مايو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights

14 مايو 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Optinose Announces Reporting Date for First Quarter 2024 Financial Results

10 مايو 2024 13:57:13 بحسب Nasdaq GlobeNewswire

Optinose Announces $55 Million Registered Direct Offering

09 مايو 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million

25 أبريل 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Optinose to Present at the Needham Virtual Healthcare Conference

04 أبريل 2024 15:01:00 بحسب Nasdaq GlobeNewswire

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

15 مارس 2024 14:34:50 بحسب Nasdaq GlobeNewswire

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

07 مارس 2024 06:00:43 بحسب Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

29 فبراير 2024 15:40:00 بحسب Nasdaq GlobeNewswire

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

18 يناير 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

06 ديسمبر 2023 06:00:00 بحسب Nasdaq GlobeNewswire